The Bull Rankings scorecard — our quality-growth score is 68.6 / 100, built from three pillars scored 0–100: Quality 68, Growth 58, Value 81 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 0% a year next year, rising to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Universal Health Services sits on a value foundation that the Bull Rankings model rates at 81. That pillar is the engine of the thesis: a P/E of 7.2 and a PEG of 1.17, coupled with a free‑cash‑flow of $845 m, signal a stock that is cheap relative to peers yet still growing. The quality score of 68 underscores a solid operating profile—ROE 20.3 % and profit margin 8.4 %—but the growth score of 58 warns that the upside is modest. In the quarter ended 2026‑06‑30, revenue climbed 10 % YoY, far above the roughly 0 % free‑cash‑flow growth the reverse‑DCF implies for next year. The market has priced in a near‑flat cash‑flow trajectory, leaving room for upside if the company can lift its operating leverage.
The single sharpest argument for UHS today is that the price assumes near‑flat cash flow while the company’s cash generation remains robust. The stock trades at $176.85, well below the analyst consensus 1‑year target of $193.94 and near the low end of the $166–$290 range. With a debt‑to‑equity of 0.69, the firm can comfortably service its obligations while returning capital through buybacks, which the model flags with its buying back stock signal. If UHS can maintain its 8.4 % margin and 20.3 % ROE, the current price offers a cushion that makes the upside attractive.
What the business actually is
UHS owns and operates acute care hospitals and outpatient and behavioral health facilities across the United States. Its Acute Care Hospital Services segment delivers general and specialty surgery, internal medicine, obstetrics, emergency care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and behavioral health services. The Behavioral Health Care Services segment focuses on psychiatric and substance‑abuse treatment. The company also offers commercial health insurance services, capital resources, and a suite of management services—central purchasing, information systems, finance and control, and facilities planning—supporting its hospital network.
Revenue growth comes from expanding service lines and adding new facilities, particularly in the behavioral health space, where demand has risen sharply. The hospital segment remains the largest revenue generator, but the behavioral health arm is a high‑margin growth engine, feeding the overall 10 % YoY revenue increase.
Why it can (or can't) keep compounding
UHS’s moat is built on scale and integration. Operating hundreds of hospitals and behavioral health facilities, the firm enjoys economies of scale in purchasing and shared services, reflected in its 8.4 % profit margin. The company’s 20.3 % ROE indicates that capital is deployed efficiently. The buying back stock signal confirms that management is confident in the cash‑flow outlook and willing to return value to shareholders.
Competing hospitals cannot replicate UHS’s network instantly. Building a comparable footprint requires significant capital, regulatory approvals, and time. Moreover, UHS’s integrated management services—central purchasing, information systems, and finance controls—give it cost advantages over smaller operators. These factors reinforce the company’s ability to sustain its current growth trajectory and maintain margin discipline.
The valuation question
The price implies a free‑cash‑flow growth of about 0 % in year 1, tapering to 3 % by year 10. That starting rate is lower than the 10 % revenue growth reported for the last twelve months, suggesting that the market is pricing in a pessimistic cash‑flow outlook. If UHS can translate its revenue expansion into cash‑flow growth, the current price would be undervalued. Conversely, if the company’s operating leverage falters and margins slip below 8.4 %, the implied flat growth would be justified, and the stock would be fairly valued or slightly overvalued.
The P/E of 7.2 sits below even the cheapest tenth of the healthcare sector. The PEG of 1.17 says analysts expect only modest earnings growth. The analyst consensus 1‑year target of $193.94 reflects a modest upside, aligning with the model’s view that the stock is currently cheap but not a runaway.
The bear case
The most compelling skeptic’s argument hinges on growth erosion. If UHS’s revenue growth stalls below the current 10 % YoY, the reverse‑DCF implied 0 % cash‑flow growth becomes realistic, and the price would be justified. A single metric that could confirm this is a drop in the profit margin below 8.4 %. Margin compression would erode free cash flow, making the current valuation less attractive. Federal cuts to Medicaid funding are a specific threat, since hospitals rely on those payments. The market’s 52‑week high of $246.33 and low of $140.08 illustrate volatility; a sustained slide toward the low end would validate the bear case.
What would change our mind
- Revenue growth falling below 5 % YoY would signal that the company cannot sustain its current expansion, weakening the value case.
- Profit margin slipping below 7 % would indicate cost pressures that could bite free cash flow, aligning the price with the reverse‑DCF’s flat growth assumption.
- Debt‑to‑equity rising above 1.0 would raise leverage concerns, weakening the quality pillar and potentially justifying a higher discount rate.
If any of these thresholds were breached, the thesis would shift from a value play to a cautious stance.